Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.
This meta-analysis examined We assessed potential surrogates for OS in patients with metastatic melanoma treated with nivolumab-containing regimens in the first-line treatment setting. Key finding: CONCLUSION: At the individual-level, ORR exhibited a strong correlation with OS, whereas PFS and TNTD showed a moderate level correlation with OS.
This meta-analysis examined We assessed potential surrogates for OS in patients with metastatic melanoma treated with nivolumab-containing regimens in the first-line treatment setting. Key finding: CONCLUSION: At the individual-level, ORR exhibited a strong correlation with OS, whereas PFS and TNTD showed a moderate level correlation with OS.
What the study was
- Study design
- Meta-analysis
- Sample size
- 1865
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
High-priority meta-analysis in Novel therapeutics (immunotherapy, CAR-T, targeted therapy); strong trial design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.